Quick answer
Oliver Grant is a Junior Pharma Data Reporter for Europe & United Kingdom pharmaceutical intelligence editor on NovaPharmaNews, with 20 published articles covering EMA regulatory actions, clinical development, and market-moving news. Oliver Grant focuses on conference datasets, endpoint interpretation, and comparative clinical performance in EU-focused programs. In 3 years of reporting, he has developed strong skills in presenting complex data in clear, decision-oriented formats.
About Oliver Grant
Oliver Grant focuses on conference datasets, endpoint interpretation, and comparative clinical performance in EU-focused programs. In 3 years of reporting, he has developed strong skills in presenting complex data in clear, decision-oriented formats.
Coverage focus
Topics and beats Oliver covers across Europe & United Kingdom.
Explore related intelligence
Entity directories linked from this author's coverage.
- Global markets Cross-region command center
- Company directory Sponsor & marketer profiles
- Drug profiles INN & regulatory status
- Clinical trials hub Stage & therapy filters
- Pipeline programs R&D intelligence
- Patent landscape US & EP IP moats
- Event calendar Congress catalysts
- Regulatory reference Submission types & pathways
Articles by Oliver Grant
Takeda's TAK-881 Meets Primary Endpoint in Phase 2/3 Trial for Primary Immunodeficiency Disease
Takeda announces positive topline results for TAK-881, showing pharmacokinetic comparability to HYQVIA in pivotal Phase 2/3 trial for PID patients.
SQ Innovation's Lasix ONYU Subcutaneous Heart Failure Trial Results to Be Presented at Heart Failure 2026
SQ Innovation announces SUBCUT HF II trial results for Lasix ONYU, the first at-home subcutaneous furosemide treatment for heart failure edema, May 9th.
GRIN Therapeutics Expands Phase 3 Beeline Study for Radiprodil to Europe for GRIN-NDD Treatment
GRIN Therapeutics initiates Phase 3 Beeline study in Europe for investigational radiprodil targeting GRIN-NDD, expanding global clinical program.
SAHPRA Accelerated Approval: What You Need to Know About Oncology Access
Learn how SAHPRA's Accelerated Approval is transforming oncology access, expediting vital treatments like Pembrolizumab for cancer patients in need.
FDA Accelerated Approval Pathway: Impact on Oncology Market Access & Pricing in 2026
This article examines how the FDA's Accelerated Approval Pathway will shape oncology market access and pricing strategies for cancer therapies in 2026.
Cancer Immunotherapies UAE: Regulatory and Access Insights 2025
This article provides essential insights into the regulatory landscape and access to cancer immunotherapies in the UAE, focusing on key drugs and future trends.
Saudi Arabian Pharmaceutical Market: Impact of SFDA's Accelerated Drug Approval
The Saudi Arabian pharmaceutical market is evolving rapidly due to the SFDA's accelerated drug approval process, enhancing access to essential medications.
ANVISA Approves Enhertu: Transforming HER2-Positive Breast Cancer Care in Brazil
Enhertu has received ANVISA approval, marking a significant advancement in the treatment landscape for HER2-positive breast cancer in Brazil.
Ray Therapeutics RTx-015 Receives EMA PRIME Designation for Retinitis Pigmentosa Treatment
Ray Therapeutics' RTx-015 gene therapy receives EMA PRIME designation for retinitis pigmentosa, accelerating regulatory pathway for vision restoration treatment.
NMPA Foreign Clinical Trial Data: What You Need to Know
This article explores the significance of NMPA foreign clinical trial data for drug approvals, focusing on its impact on cancer therapies and regulatory compliance.
SAHPRA Biosimilars Approval: Pathway Analysis and Market Implications
This article analyzes SAHPRA's biosimilars approval pathway and its market implications for biologics, impacting patient access to essential therapies.
Traditional Medicine in MEA Cancer Care: Evidence & Regulatory Insights 2024
This article delves into the integration of traditional medicine in cancer care across the MEA region, highlighting evidence and regulatory frameworks for effective treatment.
SQ Innovation's Lasix ONYU Receives CE Marking Approval, Advances Toward European Market Authorization
SQ Innovation announces CE marking for Lasix ONYU medical device under EU MDR, plus EMA centralized procedure eligibility for European market expansion.
SURPASS-CVOT Trial Results: Implications for Mounjaro's Cardiovascular Safety and FDA Labeling
The SURPASS-CVOT trial results shed light on Mounjaro's cardiovascular safety, influencing its FDA labeling and future use in diabetes management.
Guerbet's Lipiodol Ultra Fluid Achieves EU Regulatory Milestone for Vascular Embolization Procedures
Guerbet announces positive EU regulatory outcome for Lipiodol Ultra Fluid in vascular embolization, expanding interventional radiology applications.
FDA Approval VX-009: Market Analysis of Oncodex's Oncolytic Virus Therapy
Explore the implications of FDA-approved VX-009, Oncodex's groundbreaking oncolytic virus therapy, and its potential impact on the cancer treatment market.
EMA Cell Therapy Framework: Impact on CAR-T Availability in Europe
The EMA Cell Therapy Framework aims to enhance CAR-T therapy access in Europe, potentially transforming treatment options for hematological malignancies.
Healthcare Third-Party Logistics Market to Double by 2034, Reaching $502.6 Billion Driven by Pharmaceutical Growth
Healthcare 3PL market projected to grow from $246.1B to $502.6B by 2034 at 7.8% CAGR, driven by pharmaceutical expansion and cold chain logistics demand.
Biosimilars in Argentina: ANMAT Approval and Market Growth Analysis 2025
This article analyzes the approval of biosimilars by ANMAT in Argentina and projects market growth trends for 2025, highlighting key drugs and their indications.
CervoMed's Neflamapimod Shows Brain Volume Increase in Dementia with Lewy Bodies Trial at AAN 2026
CervoMed reports neflamapimod increased basal forebrain volume and connectivity in DLB patients, suggesting potential disease reversal in early stages.
Frequently asked questions
Who writes NovaPharmaNews articles?
Each story is attributed to a named editor or analyst with a public author profile. Profiles list credentials, coverage focus, and every published article so readers and AI systems can verify expertise and trace claims to a accountable journalist.
How do I find more coverage from this author?
Scroll to the article archive on this page, or use the topic chips linked from the author’s specializations. The regional authors directory lists every active contributor in this edition.
How does author coverage connect to companies and pipeline data?
Articles link to company profiles, drug INN pages, clinical trials, and pipeline programs when entities are tagged. Use the intelligence spokes on each story or browse topic hubs from the author’s beat.